Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report

Table 4

Inflammatory oxidative damage (IOD) values, oxidized LDL, and C-reactive protein (CRP) levels after treatment with regular and lycosome formulations of PC (medians with 95/5 CI).

Duration of treatment	Formulations of PC
	Regular	Lycosome
	IOD (MDA µM/ml)
Baseline	156.5 (168.7/144.8)	159.0 (169.3/145.6)
1 month	96.5 (110.4/60.4)	71.5 (83.0/57.9)
2 months	74.5 (81.0/67.2)	52.0 (64.8/44.3)
	Oxidized LDL (LDL-Px ELISA × 10^3)
Baseline	621.71 (666.25/576.15)	577.21 (605.4/549.00)
1 month	587.5 (634.4/553.0)	510.5 (549.6/483.5)
2 months	547.5 (573.5/478.7)	384.0 (409.0/353.7)
	CRP (mg/L)
Baseline	6.0 (7.3/5.4)	6.5 (7.7/5.8)
1 month	6.1 (6.6/5.4)	5.6 (6.5/5.0)
2 months	5.8 (6.3/5.3)	5.1 (5.6/4.3)

The patients were screened, enrolled, randomized, and treated with regular (PC) or lycosome (PC-Lycosome) formulations of phosphatidylcholine (PC) for 2 months as described in Materials and Methods. Median values with confidence intervals for IOD, LDL-Px, and CRP at time “0” and the end point of the study are shown above; as compared to baseline.